- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ELICERA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Mo | Elicera Therapeutics AB: Elicera announces outcome of the rights issue | 98 | GlobeNewswire (Europe) | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, ISRAEL, CANADA, JAPAN, SOUTH AFRICA, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 25.05. | Elicera Therapeutics AB: Elicera Therapeutics announces that the final reporting and final payment from the EIC Accelerator for the CARMA study have been approved | 341 | GlobeNewswire (Europe) | Gothenburg, May 25, 2026 - Elicera Therapeutics AB (publ) ("Elicera"), a clinical stage cell and gene therapy company developing next-generation therapies based on oncolytic viruses and CAR T-cells... ► Artikel lesen | |
| 13.05. | Elicera Therapeutics AB: Elicera Therapeutics' CSO takes temporary leave to undergo medical treatment - Di Yu appointed Acting CSO | 168 | GlobeNewswire (Europe) | Gothenburg, May 13, 2026 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| 12.05. | XFRA CAPITAL ADJUSTMENT INFORMATION - 12.05.2026 | 970 | Xetra Newsboard | Das Instrument MIH0 US6067934041 MITSUBISHI HEAV.IN. ADR/1 EQUITY wird cum Kapitalmassnahme gehandelt am 12.05.2026 und ex Kapitalmassnahme am 13.05.2026 The instrument MIH0 US6067934041 MITSUBISHI... ► Artikel lesen | |
| 11.05. | Elicera Therapeutics AB: Elicera publishes information document regarding the rights issue | 297 | GlobeNewswire (Europe) | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, ISRAEL, CANADA, JAPAN, SOUTH AFRICA, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 21.04. | Elicera Therapeutics AB: Elicera Therapeutics carries out a rights issue of approximately SEK 73 million | 196 | GlobeNewswire (Europe) | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, ISRAEL, CANADA, JAPAN, SOUTH AFRICA, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 21.04. | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Interim Report 1 January - 31 March 2026 | 146 | GlobeNewswire (Europe) | First quarter (January-March 2026)
Operating profit/loss amounted to SEK -5,116,779 (-8,069,404).
Loss for the period amounted to SEK -5,060,060 (-8,013,462).
Cash flow from operating activities... ► Artikel lesen | |
| 20.03. | Elicera Therapeutics AB: Elicera Therapeutics Announces Swedish Cancer Society's Senior Investigator Award to Chief Development Officer Di Yu | 230 | GlobeNewswire (Europe) | Gothenburg, March 20, 2026 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| 11.03. | Elicera Therapeutics AB: Elicera Therapeutics receives Notice of Allowance for Japanease patent protecting the ELC-401 CAR T-cell candidate | 168 | GlobeNewswire (Europe) | Gothenburg, March 11, 2023 - Elicera Therapeutics AB (publ) ("Elicera"), a clinical stage cell and gene therapy company developing next-generation therapies based on oncolytic viruses and CAR T-cells... ► Artikel lesen | |
| 10.03. | Elicera Therapeutics' Chief Scientific Officer Magnus Essand named Cancer Researcher of the Year 2026 by the Swedish Cancer Society (Cancerfonden) | 1 | Cision News | ||
| 06.03. | Elicera Therapeutics AB: Elicera Therapeutics reports complete metabolic response (CMR) and well tolerated treatment in first two patients of cohort 3 in CARMA study, bringing total CMR to 6 out of 8 treated patients | 213 | GlobeNewswire (Europe) | Gothenburg, March 6, 2026 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| 27.02. | Elicera Therapeutics AB: Elicera Therapeutics provides update on preclinical CAR T-cell program ELC-401 for glioblastoma: preclinical development concluded and clinical trial planning underway | 1.065 | GlobeNewswire (Europe) | Gothenburg, February 27, 2026 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next-generation cancer treatments based on its proprietary iTANK platform, today... ► Artikel lesen | |
| 18.02. | Elicera Therapeutics to present ipdated CARMA study data on March 6, 2026, at the 10th Zurich Immuno-Oncology Conference | 4 | Cision News | ||
| 13.02. | Elicera Therapeutics AB Q4 Loss Widens | 1 | RTTNews | ||
| 13.02. | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Year-End 1 January - 31 December 2025 | 178 | GlobeNewswire (Europe) | Fourth quarter (October-December 2025)
Operating loss amounted to o SEK -7,129,626 (-2,911,958).
Loss for the period amounted to SEK -6,965,286 (-2,603,242).
Cash flow from operating activities... ► Artikel lesen | |
| 11.02. | Elicera Therapeutics announces abstract acceptance at ISCT 2026 Dublin: Complete metabolic response achieved in four of six patients with iTANK-armed ELC-301 in CARMA Lymphoma Study | 1 | Cision News | ||
| 22.01. | Elicera Therapeutics' CSO invited to present at multiple scientific conferences | 1 | Cision News | ||
| 09.01. | Elicera Therapeutics AB: Elicera Therapeutics announces final data from its Phase I/IIa trial demonstrating a favorable safety profile and promising efficacy signals of oncolytic virus ELC-100 in neuroendocrine tumors | 224 | GlobeNewswire (Europe) | Gothenburg, January 9, 2025 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on its proprietary commercial technology... ► Artikel lesen | |
| 23.12.25 | Correction: Elicera Therapeutics AB (publ) changes Certified Adviser and Liquidity provider to DNB Carnegie Investment Bank AB (publ) | 1 | Cision News | ||
| 14.11.25 | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Interim 1 January - 30 September 2025 | 171 | GlobeNewswire (Europe) | Third quarter (July-September 2025)
Operating loss amounted to SEK 146,689 (-2,697,267).
Loss for the period amounted to SEK 304,153 (-2,514,629).
Cash flow from operating activities totaled SEK... ► Artikel lesen |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 5,305 | +0,47 % | EQS-NVR: Evotec SE: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: Evotec SE
/ Veröffentlichung der Gesamtzahl der Stimmrechte
Evotec SE: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 517,40 | +0,15 % | Is Regeneron Pharmaceuticals Stock Underperforming the Dow? | ||
| BRAIN BIOTECH | 2,960 | -1,33 % | EQS-News: BRAIN Biotech AG: BRAIN Biotech veröffentlicht Halbjahreszahlen für das Geschäftsjahr 2025/26 und bestätigt Gesamtjahresprognose | EQS-News: BRAIN Biotech AG
/ Schlagwort(e): Halbjahresergebnis/Halbjahresbericht
BRAIN Biotech veröffentlicht Halbjahreszahlen für das Geschäftsjahr 2025/26 und bestätigt Gesamtjahresprognose... ► Artikel lesen | |
| SCORPIUS | - | - | Antares Global launches Scorpius MGA platform under Ian Morris | ||
| CARDIOL THERAPEUTICS | 1,036 | -1,33 % | Cardiol Therapeutics Inc. - 6-K, Report of foreign issuer | ||
| CSL | 58,49 | +0,26 % | Historic: Here's why CSL shares are looking very interesting right now | ||
| BURCON NUTRASCIENCE | 1,160 | -0,85 % | Burcon NutraScience Corporation: Burcon Announces Appointment of New Director | Vancouver, British Columbia--(Newsfile Corp. - April 29, 2026) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) (the "Burcon" or the "Company"), a global technology leader in plant-based... ► Artikel lesen | |
| MANNKIND | 2,978 | -2,01 % | MannKind Announces FDA Approval of Afrezza, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes | Enables dosing at the start of a meal, offering flexibility for children and adolescents as they manage school, sports, meals, and snacks throughout the dayApproval advances pediatric diabetes care... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 7,750 | +0,65 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI in Wet AMD | New SOL-1 post-hoc analyses presented at VBS reinforce AXPAXLI's unmatched durability in wet AMD with sustained disease control AXPAXLI demonstrated robust CSFT control with a median time of 39 weeks... ► Artikel lesen | |
| OXFORD NANOPORE TECHNOLOGIES | 1,563 | -1,01 % | Oxford Nanopore Tech - Issue of Equity and Total Voting Rights | ||
| CODEXIS | 2,412 | +5,24 % | Codexis signs agreement to manufacture 50 g siRNA using its ECO Synthesis Manufacturing Platform | REDWOOD CITY, Calif., March 4, 2026 /PRNewswire/ -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced... ► Artikel lesen | |
| CORMEDIX | 7,182 | -1,07 % | CorMedix, Inc.: Cormedix Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | ? Q1 2026 Net Revenue of $127.4 million ? ? Q1 2026 Net Income of $38.6 million; Adjusted EBITDA of $70.0 million ? - Company raises FY 2026 Revenue and Adjusted EBITDA Guidance - ? Conference Call... ► Artikel lesen | |
| TELO GENOMICS | 0,039 | 0,00 % | Telo Genomics Corp.: Telo Genomics Announces Study with University of Athens to Advance Next-Generation MRD Risk Stratification in Multiple Myeloma | Vancouver, British Columbia--(Newsfile Corp. - April 14, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and... ► Artikel lesen | |
| ALIGOS THERAPEUTICS | 4,760 | +3,37 % | Aligos Therapeutics: Lake Street startet Coverage mit "Buy" wegen Potenzials bei Hepatitis-B-Medikament | ||
| VTV THERAPEUTICS | 28,000 | -0,71 % | vTv Therapeutics Inc.: vTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | Phase 3 CATT1 completion of enrollment on track for the third quarter of 2026 Strong balance sheet expected to fund operations through anticipated CATT1 topline data readout HIGH POINT, N.C., May... ► Artikel lesen |
Das Unternehmen ELICERA THERAPEUTICS AB kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,250 Euro und damit +0,40 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ELICERA THERAPEUTICS AB finden Sie auf Wallstreet Online.